Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Up 47.1% in July

Hookipa Pharma Inc (NASDAQ:HOOK) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 95,300 shares, an increase of 47.1% from the June 30th total of 64,800 shares. Based on an average trading volume of 86,400 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.2% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Hookipa Pharma stock. Acadian Asset Management LLC increased its stake in Hookipa Pharma Inc (NASDAQ:HOOK) by 85.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 882,262 shares of the company’s stock after acquiring an additional 407,532 shares during the period. Acadian Asset Management LLC owned approximately 0.89% of Hookipa Pharma worth $627,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 63.88% of the company’s stock.

Analyst Ratings Changes

HOOK has been the topic of several research reports. JMP Securities reduced their target price on Hookipa Pharma from $50.00 to $23.00 and set a “market outperform” rating on the stock in a report on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Hookipa Pharma in a report on Tuesday, May 21st. Finally, HC Wainwright lifted their target price on Hookipa Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, June 5th.

Hookipa Pharma Price Performance

Shares of HOOK stock traded down $0.45 during trading hours on Monday, hitting $5.70. The stock had a trading volume of 27,724 shares, compared to its average volume of 69,304. Hookipa Pharma has a one year low of $4.10 and a one year high of $11.30. The stock’s 50-day moving average price is $7.01 and its two-hundred day moving average price is $7.29. The stock has a market capitalization of $56.40 million, a price-to-earnings ratio of -1.14 and a beta of 0.81.

Hookipa Pharma (NASDAQ:HOOK) last released its quarterly earnings results on Thursday, May 9th. The company reported $1.20 EPS for the quarter, topping the consensus estimate of ($1.20) by $2.40. The company had revenue of $36.60 million during the quarter, compared to analyst estimates of $3.20 million. Hookipa Pharma had a negative return on equity of 33.33% and a negative net margin of 88.73%. During the same quarter last year, the business posted ($2.70) earnings per share. As a group, equities research analysts predict that Hookipa Pharma will post -2.57 earnings per share for the current fiscal year.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.